Literature DB >> 10895245

Treatment of parkinsonian syndromes in developing countries.

A Ogunniyi1.   

Abstract

Parkinsonism is the commonest extrapyramidal disorder. The condition arises when the striatonigral dopamine content falls below a critical value. The principle of treatment is dopamine replacement or counteracting the effects of acetycholine, the neurotransmitter which is in abundance. The choice of drug is determined by availability, cost, and side effects. The most commonly prescribed drugs in developing countries are the anticholinergics, which are the least expensive. The dopamine-replacement agents are second-line drugs and it appears as if low doses are effective in improving rigidity, gait abnormality, and postural instability. The use of dopa-agonist drugs is more limited, because of cost and side effects. Surgical management of cases is still in its infancy in developing countries. This review also highlights the more recent modes of management practised mainly in developed countries.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10895245

Source DB:  PubMed          Journal:  Afr J Med Med Sci        ISSN: 0309-3913


  4 in total

1.  Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania.

Authors:  Catherine Dotchin; Ahmed Jusabani; Richard Walker
Journal:  J Neurol       Date:  2011-03-26       Impact factor: 4.849

2.  Burden of adult neurological diseases in Odeda Area, Southwest Nigeria.

Authors:  Folajimi Morenikeji Otubogun; Rufus Akinyemi; Sola Ogunniyi
Journal:  BMJ Neurol Open       Date:  2020-08-24

3.  The Accessibility of Parkinson's Disease Medication in Kenya: Results of a National Survey.

Authors:  Jolynne Mokaya; Catherine L Dotchin; William K Gray; Juzar Hooker; Richard W Walker
Journal:  Mov Disord Clin Pract       Date:  2016-01-09

Review 4.  Parkinson's Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care.

Authors:  Uduak Williams; Oliver Bandmann; Richard Walker
Journal:  J Mov Disord       Date:  2018-05-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.